DNER and plasma cell myeloma: Currently, some BET inhibitors such as OTX015 and CPI-0610 exhibited well anti-myeloma activities in vitro and in vivo, which had been approved to conduct clinical I phase studies (NCT02157636, NCT 01713582) [32, 33].